Kromek Share Discussion Threads

[strategicinvestor2] 12/12/2022 13:55

Broker reiterates valuation over 150% above current share price. Any views ??

[strategicinvestor2] 12/12/2022 12:53

Don’t miss out lol

Wonder which European countries the new order is from ??

[ark87] 12/12/2022 12:47

Chart now looks great but can't bring myself to add beacuse of the risk of anonther placing.

[estienne] 12/12/2022 09:18

£7.5M in new orders in last 6 weeks does make me feel a bit more optimistic

[andyview] 12/12/2022 08:40

Further good news today, I keep adding a few as I can


Gla

[strategicinvestor2] 12/12/2022 07:41

Excellent news, another new contract win. Relatively small but these add up. Onwards and upwards. DYOR GLA

[ramnik007] 12/12/2022 07:31

Let's hope all the R&D spend is now starting to generate the sales required to stop further fund raise.

[33mick] 08/12/2022 14:11

This is the latest info regarding the Bio airborne pathogen programme...being presented in USA this week

2022 Chemical and Biological Defense Science & Technology (CBD S&T) Conference
06 Dec - 09 Dec 2022
Moscone Center, San Francisco, California, USA

NEXT-GENERATION BIOAEROSOL DETECTION & IDENTIFICATION
Kromek Automated Pathogen Scanner - Air Sequencing (kapscan-as):
Agnostic Airborne Pathogen Detection And Identification Via Fully
Automated And Autonomous Long Read Sequencing
Jamie Marsay Kromek Raad Mahmoud Kromek Anastasios Chanalaris Kromek Dirk Demuth Kromek
Background information: Minimising the impact of pathogen-initiated outbreaks, whether naturally occurring or intentional biological attacks,
depends on our ability to detect and identify the causative agent, in order to diagnose, properly triage and treat those infected, and gauge the
extent and dynamics of an outbreak. DNA sequencing can provide a sample’s constitution and its pathogenic burden. Advances in genome
engineering (e.g., CRISPR) and synthetic biology mean that variations of pathogens can be created as bioweapons which evade detection by
standard targeted techniques like PCR.
Purpose/Methods: We are developing a novel fully automated and autonomous biosensing system (KAPscan-AS (Kromek Automated Pathogen
Scanner–Air Sequencing)) that detects the presence of airborne pathogens (viral and bacterial) based on long read sequencing. Our integrated
environmental monitoring system allows early detection of any biological threat across large areas and can inform appropriate and timely response
to a potential threat.
Objective/Rationale/Results: We are developing a mobile version of KAPscan-AS for a proof-of-concept study. This device will be capable of rapidly
identifying the pathogens used in any biological attack in an urban environment. The device collects autonomously and continuously air samples
which are immediately processed and analysed. Our end-to-end sample processing pipeline consists of air sampling, wet lab, and data analysis.
KAPscan-AS collects air via a bespoke wide area air sampler, concentrates the air and collects pathogens in a liquid phase. Viral and bacterial
pathogens are separated by filtration and processed in two parallel pipelines through a modular system of several alternating steps using
microfluidic and millifluidic solutions (concentration, lysis, clean up, amplification, library preparation, sequencing). Proprietary software maps the
generated data against all organisms and delivers fast results on a species level in under 20 min. The results do not require analysis by trained
individuals or specialist laboratories. The whole process takes 2 hours from collection to results. The information is reported back to central base
over a data aggregation network. Our system identifies a panel of 40 pathogens with future upgrades moving towards agnostic detection of
unknown pathogens.
Impact to the DTRA mission and war fighter: Our ongoing systems integration for non-scientific end-users (e.g., war fighters) and cost-down work
will result in a commercial system which can achieve widespread adoption within mobile and static CBRN applications. KAPscan-AS can either be
deployed as an autonomous system for monitoring air or an automated portable sequencing lab with minimal user interaction. As an early warning
system it can operate both as a standalone device in a specific location, and as part of a network of monitoring devices. This will allow fast
actionable information to military authorities without resource burden. In-field analysis of suspicious samples provides results which are rapidly
available to troops. Threats are identified down to strain level and countermeasures can be rapidly enacted. This has recently been recognized
when KAPscan-AS won first prize at the NATO Innovation Challenge ̵6;Bioresponse’. Our novel technology will make ubiquitous DNA sequencing a
reality and finally transform DNA sequencers into sensors.
Approved for public release; distribution is unlimited.

[strategicinvestor2] 30/11/2022 19:51

Excellent summary Cat. GLA

[catabrit] 30/11/2022 13:16

If shareholder value isn't realised soon, someone will take a stake and call for a strategic review. It makes no sense to me that their key competitor was acquired for almost 5x the current share price and the share price is languishing at all time lows (disclaimer: my basis is 10p as I only discovered this biz a few days' ago). Even assuming that was top of the market price to sales and applying a massive haircut, we're still getting the other division for free. These sorts of valuable assets don't tend to stay cheap / undiscovered forever. If the operational gearing doesn't kick in soon, they will be forced to do something about it. A decade is a long time to wait for the 'story' to finally come true.

[aqc888] 30/11/2022 11:26

Any investor in Kromek has to understand that the management here is extraordinarily weak, with an aweful record of never achieving their aims.

It’s possible value can be extracted here via sale of part of business or a strategic tie up. But investing here hoping that the management will suddenly change is a fool’s errand.

If you see any fund manager being interviewed about how they pick investments you’ll often see a strong management team as pretty high up. There’s a reason for this. As a previous investor of Kromek I’m extremely irritated by the ineptness of the board.

[andyview] 30/11/2022 10:12

Could be right strategic, just seen another 100k buy hit the market, looks very promising.

gla

[strategicinvestor2] 30/11/2022 09:54

Some stake building could be starting ??

[andyview] 30/11/2022 09:44

We've got buyers today coming in for 100k sizes and loads of little nibbles too. NT at the moment to buy, is this the corner approaching?

gla

[andyview] 30/11/2022 09:37

I'm willing to give him the benefit of the doubt here, progress is happening from the evidence of recent announcements alone. You cant deny the area of expertise isn't at the forefront of of many governments :

Arnab Basu, CEO of Kromek Group, said: "We are delighted to have been awarded this contract to develop and supply an important capability for biological threat detection. The pandemic has demonstrated the impact of biological incidents - whether it is through an act of terror or naturally emerging threats. Governments throughout the world are reviewing their strategies to update their defence against such threats. We believe technologies that can provide information about emerging threats in near real time will be a critical component of such strategies."

gla

[andyview] 30/11/2022 09:10

We had this little snippet dated the 10/11:

Dr Arnab Basu, Chief Executive Officer of Kromek, said: "We are pleased to win this contract for our D3M radiation detectors. This repeat order affirms the strength of our nuclear radiation detection technology and highlights the growing market demand for these products. It is also reflective of the strong trading that we experienced in the first half of our FY 2023 year, and we expect to report revenue growth of approximately 45% for the six months to 31 October 2022. This, combined with the momentum that we are seeing, particularly in the CBRN segment, underpins the Board's confidence in our prospects for the future."

gla

[andyview] 30/11/2022 09:05

We've seen positive news releases and an uptick in the volume traded, this has coincided with a start of an uptrend in the price. I'm looking for a sustained rerate, all imho of course.

gla

[aqc888] 29/11/2022 19:58

The thing with Kromek is, that you can never believe what they say. They said the biological pathogen detector had passed its accreditation brilliantly with accuracy equivalent to a pcr test, the trials all went well and sales were due at the beginning of this year. No sales materialised and no explanation was given. Same story as the ventilators. Kromek even had a liquid bomb detector for airports they developed… these are rolling out in airports now I see in the news (only not Kromeks version).
Kromeks share price has been rightly battered. The last £13m fundraising was in large part to commercialise the biological pathogen detector… yet there has been no commercialisation. They just received a £5m contract from the government to develop it - how could they commercialise something years ago that apparently isn’t developed yet??!! Bizarre. The only constant with Kromek is failure.

[andyview] 29/11/2022 13:17

Decided to take a few more anyway

Gla

[andyview] 29/11/2022 12:45

Buying interest today, nearly added this morning too 🤦

Gka

[estienne] 29/11/2022 10:03

Except that this time the price hasn't risen on the tip which implies that investors have got wise to it. I wonder what motivates ST to tip them when they perform so badly?